flixotide inhaler cfc free 250 mcg
glaxo smith kline (israel) ltd - fluticasone propionate - suspension for inhalation - fluticasone propionate 250 mcg/dose - fluticasone - fluticasone - prophylactic management of all grades of asthma.fluticasone propionate is indicated for the management of copd when used in combination with long-acting bronchodilators (e.g. long-acting beta agonists (labas)).
flutiform 250 microgram/10 microgram per metered dose pressurised inhalation, suspension
mundipharma pharmaceuticals limited - fluticasone propionate; formoterol fumarate dihydrate - pressurised inhalation, suspension - 250 µg/10 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and fluticasone
flixotide evohaler 250 micrograms, per metered dose, pressurised inhalation, suspension
ltt pharma limited - fluticasone propionate - pressurised inhalation, suspension - 250 mcg/dose - glucocorticoids; fluticasone
fluhale inhaler fluticasone propionate 125 microgram/actuation inhalation pressurised aerosol can metered dose
cipla australia pty ltd - fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for use in the prophylactic management of asthma in adults and adolescents over 16 years of age.
fluair inhaler fluticasone propionate 125 microgram/actuation inhalation pressurised aerosol can metered dose
cipla australia pty ltd - fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for use in the prophylactic management of asthma in adults and adolescents over 16 years of age.
evocair mdi 50/25 fluticasone propionate 50 mcg/salmeterol (as xinafoate) 25 mcg inhalation pressurised aerosol can metered dose (with counter)
glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 50 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials).,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. evocair is not indicated for the initiation of bronchodilator therapy in copd.
evocair mdi 50/25 fluticasone propionate 50 microgram/salmeterol (as xinafoate) 25 microgram inhalation
glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 50 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials).,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. evocair is not indicated for the initiation of bronchodilator therapy in copd.
airzate mdi 50/25 fluticasone propionate 50 microgram/salmeterol (as xinafoate) 25 microgram inhalation
glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 50 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials).,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. airzate is not indicated for the initiation of bronchodilator therapy in copd.
arquist 250 microgram per actuation pressurised inhalation, suspension
cipla europe nv - fluticasone propionate - pressurised inhalation, suspension - 250 mcg/acutuation - glucocorticoids; fluticasone
flutiform 250 microgram/10 microgram per metered dose pressurised inhalation, suspension
imed healthcare ltd. - fluticasone propionate; formoterol fumarate - pressurised inhalation, suspension - 250/10 µg/µg - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and fluticasone